Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deficit Super Committee Inaction May Be Best Scenario For Biopharma

Executive Summary

It may be a best-case scenario for the biopharmaceutical industry if the Joint Select Committee on Deficit Reduction is unable to produce a proposal by Thanksgiving to cut the federal deficit by at least $1.2 trillion over 10 years.

You may also be interested in...



"Medicare Exchange" Proposal From Healthcare Leadership Council Could Deter Threat Of Part B Drug Payment Reductions

Healthcare Leadership Council sends "super committee" recommendations, including Medicare reforms, that could save $410 billion in health care costs.

GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.

GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel